OmniGraf Liver
It is a diagnostic biomarker panel developed to detect kidney transplant rejection at its earliest stages, enabling timely and personalized treatment adjustments. This non-invasive test combines two advanced technologies:
- TruGraf® Blood Gene Expression Test: Measures gene expression profiles in the blood to identify immune responses indicative of rejection.
- Viracor TRAC® Donor-Derived Cell-Free DNA Assay: Detects fragments of DNA originating from the donor kidney, which can increase during rejection episodes.
By integrating these two methodologies, OmniGraf™ provides a comprehensive assessment of both subclinical and clinical acute rejection, offering high positive and negative predictive values. This approach allows for early intervention, potentially improving graft survival and patient outcomes.
OmniGraf
The test requires a simple blood draw of 6 milliliters, facilitating routine monitoring without the need for invasive procedures. This ease of use makes it a valuable tool for clinicians in managing kidney transplant recipients.
OmniGraf™ is part of a broader initiative to enhance transplant diagnostics, aiming to reduce the risk of rejection and improve long-term graft function through personalized medicine.
Imported & Distributed by Duraent Lifesciences in India.
100
Reduced Hospital Stays
500
Improved Transplant Outcomes
4200
Smiling Customer
